Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

References

• American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/
   Google Scholar
• Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB. Microarray-Based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. Lab Medicine 2010; 41:364-72; http://dx.doi.org/10.1309/LMLIK0VIE3CJK0WD
   Web of Science ®Google Scholar
• http://www.cancer.gov/types/breast/patient/breast-treatment-pdq
   Google Scholar
• Kern P, Kalisch A, Kolberg HC, Kimmig R, Otterbach F, von Minckwitz G, Sikov WM, Pott D, Kurbacher C. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. Chemotherapy 2013; 59:387-94; PMID:24852315; http://dx.doi.org/10.1159/000362756
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175
   PubMed Web of Science ®Google Scholar
• Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-65; PMID:20531380; http://dx.doi.org/10.1038/nrclinonc.2010.82
   PubMed Web of Science ®Google Scholar
• Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013; 18:193-201; PMID:22868084; http://dx.doi.org/10.1016/j.drudis.2012.07.015
   PubMed Web of Science ®Google Scholar
• Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73-80; PMID:11863115; http://dx.doi.org/10.1093/annonc/mdf013
   PubMed Web of Science ®Google Scholar
• http://clinicaltrials.gov/.
   Google Scholar
• Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12:R26; PMID:20459744; http://dx.doi.org/10.1186/bcr2570
   PubMed Web of Science ®Google Scholar
• Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004; 58:447-50; PMID:15464874; http://dx.doi.org/10.1016/j.biopha.2004.08.006
   PubMed Web of Science ®Google Scholar
• Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 2013; 49:3387-95; PMID:23880474; http://dx.doi.org/10.1016/j.ejca.2013.06.038
   PubMed Web of Science ®Google Scholar
• Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62:2731-5; PMID:12019144
   PubMed Web of Science ®Google Scholar
• Wang R, Qin S, Chen Y, Li Y, Chen C, Wang Z, Zheng R, Wu Q. Enhanced antitumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer. Oncol Rep 2012; 28:439-45; PMID:22641525; http://dx.doi.org/10.3892/or.2012.1828
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61:353-62; PMID:21915801; http://dx.doi.org/10.1007/s00262-011-1106-3
   PubMed Web of Science ®Google Scholar
• Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19:1737-46; PMID:21673660; http://dx.doi.org/10.1038/mt.2011.113
   PubMed Web of Science ®Google Scholar
• Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21:1212-23; PMID:23546299; http://dx.doi.org/10.1038/mt.2013.51
   PubMed Web of Science ®Google Scholar
• Bramante S, Kaufmann JK, Veckman V et al. Treatment of melanoma with a serotype 5/3 Chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int J Cancer 2015 Oct 1; 137(7):1775-83; PMID:25821063; http://dx.doi.org/10.1002/ijc.29536
   Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/10.1038/mt.2010.161
   PubMed Web of Science ®Google Scholar
• Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. In J Cancer 2014; 135:720-30; PMID:24374597; http://dx.doi.org/10.1002/ijc.28696
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tahtinen S, Oksanen M, Heiskanen R, Pesonen S et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19:2734-44; PMID:23493351; http://dx.doi.org/10.1158/1078-0432.CCR-12-2546
   PubMed Web of Science ®Google Scholar
• Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tahtinen S, Guse K, Cerullo V, Kanerva A, Kipar A et al. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer 2015; 136:945-54; PMID:24975392; http://dx.doi.org/10.1002/ijc.29048
   PubMed Web of Science ®Google Scholar
• Shanafelt AB, Johnson KE, Kastelein RA. Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J Biol Chem 1991; 266:13804-10; PMID:1856212
   PubMed Web of Science ®Google Scholar
• Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012; 20:1821-30; PMID:22871667; http://dx.doi.org/10.1038/mt.2012.115
   PubMed Web of Science ®Google Scholar
• Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimaki A, Koski A, Liikanen I et al. Immunological data from cancer patients treated with Ad5/3 E2F Delta24 GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015; 6:4467-81; PMID:25714011; http://dx.doi.org/10.18632/oncotarget.2901
   PubMed Web of Science ®Google Scholar
• Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela A, Oksanen M, Partanen K, Laasonen L, Kairemo K, Joensuu T et al. (18)F-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 2013; 24:1029-41; PMID:24099555; http://dx.doi.org/10.1089/hum.2013.123
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja M et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70:4297-309; PMID:20484030; http://dx.doi.org/10.1158/0008-5472.CAN-09-3567
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, Alemany R. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther 2009; 16:1441-51; PMID:19710704; http://dx.doi.org/10.1038/gt.2009.103
   PubMed Web of Science ®Google Scholar
• Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 2010; 16:3035-43; PMID:20501623; http://dx.doi.org/10.1158/1078-0432.CCR-09-3167
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937-47; PMID:21630267; http://dx.doi.org/10.1002/ijc.26216
   PubMed Web of Science ®Google Scholar
• Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T, Kanerva A, Pesonen S, Alemany R, Hemminki A. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 2012; 20:221-9; PMID:22044933; http://dx.doi.org/10.1038/mt.2011.230
   PubMed Web of Science ®Google Scholar
• Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12:1198-205; PMID:15800658; http://dx.doi.org/10.1038/sj.gt.3302517
   PubMed Web of Science ®Google Scholar
• Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18:251-63; PMID:20029399; http://dx.doi.org/10.1038/mt.2009.283
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6:879-85; PMID:10932224; http://dx.doi.org/10.1038/78638
   PubMed Web of Science ®Google Scholar
• Sladek NE. Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism. Cancer Res 1972; 32:1848-54; PMID:4641276
   PubMed Web of Science ®Google Scholar
• Ginsberg AH, Monte WT, Johnson KP. Effect of cyclophosphamide in vitro and on vaccinia virus replication in tissue culture. J Virol 1977; 21:277-83; PMID:833925
   PubMed Web of Science ®Google Scholar
• Ranki T, Sarkioja M, Hakkarainen T, von Smitten K, Kanerva A, Hemminki A. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 2007; 121:165-74; PMID:17315187; http://dx.doi.org/10.1002/ijc.22627
   PubMed Web of Science ®Google Scholar
• Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M, Kanerva A, Hakkarainen T, Hemminki A. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007; 6:2728-36; PMID:17938266; http://dx.doi.org/10.1158/1535-7163.MCT-07-0176
   PubMed Web of Science ®Google Scholar
• Kanerva A, Raki M, Ranki T, Sarkioja M, Koponen J, Desmond RA, Helin A, Stenman UH, Isoniemi H, Hockerstedt K et al. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med 2007; 9:3-9; PMID:17149790; http://dx.doi.org/10.1002/jgm.984
   PubMed Web of Science ®Google Scholar
• Cohen AM, Hines DK, Korach ES, Ratzkin BJ. In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56:2861-5; PMID:2459064
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66:1270-6; PMID:16452178; http://dx.doi.org/10.1158/0008-5472.CAN-05-3497
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983; 309:883-7; PMID:6310399; http://dx.doi.org/10.1056/NEJM198310133091503
   PubMed Web of Science ®Google Scholar
• Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brucher B, Stojadinovic A, Man YG. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 2014; 5:3-24; PMID:24396494; http://dx.doi.org/10.7150/jca.7709
   PubMed Web of Science ®Google Scholar
• Hemminki A. Treatment of chemotherapy-refractory cancer in the advanced therapy access program. Mol Ther 2012; 20:1654-5; PMID:22945227; http://dx.doi.org/10.1038/mt.2012.170
   PubMed Web of Science ®Google Scholar
• Hemminki A, Oksanen M, Merisalo-Soikkeli M. Oncolytic virotherapy trials–letter. Clin Cancer Res 2013; 19:4541-2; PMID:23946419; http://dx.doi.org/10.1158/1078-0432.CCR-13-1471
   PubMed Web of Science ®Google Scholar
• www.oncos.com.
   Google Scholar
• Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58; PMID:12946318; http://dx.doi.org/10.1016/S1525-0016(03)00200-4
   PubMed Web of Science ®Google Scholar
• Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8:275-80; PMID:11801569
   PubMed Web of Science ®Google Scholar
• Hemminki A. Oncolytic immunotherapy: where are we clinically? Scientifica 2014; 2014:862925; PMID:24551478; http://dx.doi.org/10.1155/2014/862925
   PubMedGoogle Scholar